Eisai Co., Ltd. (4523.T)
Develops and sells cancer and brain disease medications worldwide
5,110.00+0.07%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+20.2%
The outlook
Eisai trades near the top of its 52-week range and above both its 50- and 200-day moving averages, showing upward momentum. Analysts lean bullish with a "Buy" consensus, though their average price target sits about 12% below the current price, suggesting some caution at current levels. The stock's elevated valuation (P/E of 37.4) reflects high market expectations.
What’s behind the score
Analyst consensusBuy — 2.5 avg of 14 analysts
Price trendAbove its 50- & 200-day averages
52-week range86% of the way from its 52-week low to high
Price targetAvg target -12% vs current price
Analyst price target
~12-month · 14 analysts4,482.14average target-12.3% vs now
Now 5,110.00
Low 3,200.00High 5,500.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.44T
52-wk high
5,349.00
52-wk low
3,660.00
50-day avg
4,113.26
200-day avg
4,568.51
Trailing P/E
37.4